
👋 Hey, let’s get into it. Two weeks ago, we called Summit’s lung cancer drug, ivonescimab, the belle of the biotech ball. Pharma companies came from far and wide to partner on it. AstraZeneca had just put $2 billion into Summit. Then the FDA showed up with a clipboard.
On Sunday, Summit said the FDA rejected its bid to use ivonescimab with chemo for advanced lung cancer after prior EGFR-targeted treatment. The Phase 3 combo delayed progression, and Summit says the sticking point was that the survival benefit fell short of statistical significance.
Ivonescimab still has a shot in the U.S. though. Summit can go back to the FDA and make the case for using it in a different setting.
📰 Headliners

👁️ J&J Buys Ollin Biosciences for $2.2 Billion Upfront
Johnson & Johnson agreed to buy Ollin Biosciences for $2.2 billion upfront, with about $1.1 billion more tied to milestones. The prize is OLN324, a Phase 3 antibody that targets two signals involved in abnormal blood vessel growth and leakage in the retina. Ollin is developing it for wet age-related macular degeneration and diabetic macular edema, two major causes of vision loss. If the acquisition closes, Blackstone will separately put up $750 million to fund Phase 3 development. J&J gets a late-stage contender in a crowded market where dosing frequency can matter as much as the eye chart.
🩸 Lilly Acquires Calytrix Bio for Up to $1.5 Billion
In its ongoing search for ways to spend its GLP-1 riches, Lilly has found another biotech to buy. This time it’s Calytrix Bio, in a deal worth up to $1.5 billion including clinical and regulatory milestones. The upfront payment is undisclosed. Calytrix’s lead antibody is still preclinical and designed to target mutant forms of calreticulin, a protein that can drive two blood cancers. One, essential thrombocythemia, causes the body to make too many platelets. The other, myelofibrosis, scars the bone marrow and disrupts blood cell production. Lilly’s bet is that targeting the mutant protein can change how those diseases progress.
⏱️ FDA’s Fast Review Voucher Pilot Appears Stalled…Maybe?
The FDA’s Commissioner’s National Priority Voucher pilot was supposed to get certain drug reviews down to one or two months. Reuters reports that no new vouchers have gone out since May and the council overseeing the pilot has gone quiet. HHS says the program is still running while the FDA reviews feedback and refines it. So depending on whom you ask, the express lane is either stalled or undergoing some very deliberate refinements. The pilot is separate from the older program whose vouchers companies can buy and sell.
💉 Blackstone Puts Up to $1.5 Billion Behind Pfizer’s Monthly GLP-1
Funds managed by grill manufacturer Blackstone will cover up to $1.5 billion of development costs through 2028 for Pfizer’s berobenatide, an investigational GLP-1 being tested as a monthly shot. Pfizer keeps ownership and calls the shots on development. Blackstone can earn payments if the FDA approves the monthly shot as a stand-alone treatment and it hits sales milestones. Pfizer has 10 Phase 3 trials underway or planned for berobenatide. A monthly shot could give Pfizer a way to stand out in a market built around weekly injections, but getting it there is a big enough lift to bring a gym buddy.
📫 A Message from BioNucleus Network

🥱 Your company newsletter isn’t generating leads. It’s also boring. Sorry, but someone had to say it. The good news? It’s not your fault.
Your marketing team is probably 2.5 people on a good day, handling everything from conferences and product launches to arguing with sales about what counts as a hot lead. Finding time to turn the newsletter into something that actually helps move prospects toward a conversation? Somewhere below “fix the booth banner.”
We get it. Let BioNucleus take the newsletter off your hands.
Led by the founder and writer of BioNucleus Briefing, our newsletter service turns your company’s expertise, updates, and customer stories into newsletters built to keep prospects interested and create more opportunities for leads and sales.
We handle everything from planning through publishing. You bring the expertise and final approval.
Reply to this email with “write my newsletter” to learn more.
⚡️ Quick Hits
🧬 DeepMind’s AlphaGenome 2 Predicts DNA Effects by Cell Type
Google DeepMind’s model predicts how DNA variants alter gene activity in specific cell types, helping researchers decide which variants to test in the lab.
👍 AstraZeneca’s Keytruda Rival Wins FDA Approval With Padcev Before Bladder Cancer Surgery
Keytruda rival Imfinzi joins Padcev before surgery for adults with muscle-invasive bladder cancer who can’t take or decline cisplatin. Imfinzi continues alone afterward.
🪓 Cellectis Plans to Cut Up to 70% of Its Workforce
The planned global cuts span 2026 and 2027 as Cellectis winds down internal CAR-T programs and shifts toward editing genes inside the body.
✅ Roche’s Gazyva Wins First FDA Approval for a Rare Autoimmune Kidney Disease
Gazyva is approved for adults with primary membranous nephropathy at risk of progression, with the goal of stopping excess protein from leaking into urine.
🇨🇳 China Dismisses Two Researchers After Probe Into Child’s Death in Gene-Editing Study
Chinese state media reported the dismissals after investigators cited failures in safety disclosure and informed consent, along with omission of the death from a paper.
💉 Novo’s Lower CagriSema Doses Deliver 21% Weight Loss
Novo estimates both lower doses led to about 21% average weight loss versus 2% with placebo over 68 weeks.
💼 AstraZeneca Reportedly Cuts 600 U.S. Commercial Roles
Bloomberg reports the cuts hit AstraZeneca’s respiratory and immunology sales teams, with some staff expected to move into other roles within the company.
🧐 Deep Dive

💸 Your Drug Got Approved. Good Luck Breaking Even.
Getting a drug approved feels like the finish line. The clinical team can finally breathe, and the company can start selling. Then someone from Finance walks into the approval party and asks, “So…how many prescriptions until we get our money back?”
In a November 9 report, IQVIA modeled the lifetime economics of 825 novel medicines launched in the U.S. from 1991 to 2020. For drugs launched from 2016 to 2020, it projects that roughly nine in ten will fall short of earning a positive lifetime return. About half of the early-1990s launches cleared that bar in the model.
Why did the bar move? The analysis counts operating costs and taxes alongside R&D, and it accounts for the years that money is tied up before a drug earns its first dollar. Under those assumptions, the lifetime revenue associated with breaking even rose from $1.4 billion for the earliest group to nearly $12 billion for the latest one.
Sales are wildly uneven, too. Across the full study, about one in ten medicines accounted for 56% of lifetime revenue. A hit can help fund the rest of a portfolio, and a drug can make a meaningful difference for patients while falling short financially. The estimates also depend on what IQVIA assumes about future sales and costs.
That’s the backdrop for deals like Pfizer’s with Blackstone. Pfizer gets help with the trial bills now, and Blackstone gets a shot at payments tied to approval and sales later. The money starts going out years before anyone knows how many prescriptions will come in. No wonder so much of the negotiating happens before there’s even a product to sell.
🔢 Key Figure
26 years
That’s how long the U.S. held measles elimination status…until now. The Pan American Health Organization told U.S. officials the country has lost the designation. Health officials found evidence that the same measles strain had been spreading within the U.S. for at least a year.
🌎 Community Vibes
🧪 Scientists Confess Their Worst Lab Mistakes
On r/biotech, one person ran a gel backward. Another spent two days purifying a sticky protein, then accidentally poured it down the sink. I once spilled ethanol across my bench while working aseptically and accidentally set it on fire. The bench survived, and I maintain it was sterilized. I’ve also melted my share of things in the autoclave. Mostly by accident. Reply with your own lab failure. If enough of you write in, we’ll share a couple in the next issue. Bonus points if you have photos of the aftermath.
📚 The Books BioNucleus Subscribers Are Reading
On Thursday, we asked what science books you’d put on our reading list. You recommended The Immortal Life of Henrietta Lacks by Rebecca Skloot, a classic about the woman behind HeLa cells, and Being Mortal by Atul Gawande, for its look at hospice and what matters to patients near the end of life. You also sent in Shawn Otto’s The War on Science, a decade-old book that still feels timely. Thanks for writing in. I always love hearing from you. Feel free to reply anytime!
🧬 BioBits
🇬🇧 Flagship Puts £100 Million Into a London AI Startup Lab
Flagship Pioneering’s London lab will build companies around AI and is the firm’s first dedicated operation for creating startups outside the United States.
💊 CVS Models a $350 Monthly Break-Even Price for GLP-1s
Using Aetna claims, CVS estimated a net price around $350 per month would balance GLP-1 spending with observed medical savings over three years.
🧠 A Protein Atlas Reveals What Gets Through the Blood-Brain Barrier
In mice, researchers tracked 861 proteins in the blood and built an atlas of the 92 that crossed the barrier into the brain.
🌍 Most Countries Have Antimicrobial-Resistance Plans. Far Fewer Fund Them
WHO said 173 countries had plans to fight antimicrobial resistance. Only 42 said they’d funded and implemented them. The paperwork is ahead of the rollout.
🚀 Startup Spotlight
🐺 Seawolf Debuts With $100 Million and a $1.2 Billion Sanofi Deal
Seawolf Therapeutics surfaced with $100 million in financing and a Sanofi deal for bleeding disorders and other undisclosed indications worth up to $1.2 billion in milestones, plus royalties. The biotech uses lipid nanoparticles to deliver DNA that tells cells to make therapeutic proteins. It’s still preclinical, and the hope is that patients could receive repeat doses. Also, Seawolf is a great company name. I spent ten minutes reading about actual sea wolves before I got back to the press release.
🗓️ This Day in History
🧐 November 17, 1922: The Scientist Who Followed Some Very Strange Side Effects Is Born
Biochemist Stanley Cohen was born in Brooklyn on this day in 1922. Decades later, while studying nerve growth, he noticed that newborn mice given salivary gland extracts opened their eyes early and got their first teeth ahead of schedule. The mice had wandered well outside the original research question. Cohen followed the clue to epidermal growth factor, and he and Rita Levi-Montalcini shared the 1986 Nobel Prize for their growth factor discoveries. Today, the receptor for that factor, EGFR, is a major target for cancer drugs.
🤔 Final Thoughts
Thinking back on my lab mishaps, the one that probably caused the most trouble for other people was my handwriting. I can barely read it myself. My condolences to whoever picked up my grad school experiments where I left off. You probably spent weeks deciphering that notebook.
That’s all for today. See you Thursday for the next issue.
✍️ Today’s email was brought to you by Josh Martin. Connect with me on LinkedIn.
🤩 Your Boss Thinks You’re a Marketing Genius
You found a way to get your product in front of biotech and pharma pros who already make time to read BioNucleus Briefing twice a week. You even got the newsletter’s team to help write the ad.
When your boss asks how you pulled it off, just say, “I know a guy.”
If you’re enjoying BioNucleus, share it with a friend or coworker who’d get value from it. We’re a small operation, and every share makes a bigger difference than you think.
Was this email forwarded to you? Sign up here 👇
Follow us on social and stay one step ahead